We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Black Diamond (BDTX - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Black Diamond is a member of the Medical sector. This group includes 972 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Black Diamond is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for BDTX's full-year earnings has moved 37.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BDTX has gained about 53.3% so far this year. Meanwhile, stocks in the Medical group have lost about 1.9% on average. This means that Black Diamond is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Cidara Therapeutics (CDTX - Free Report) . The stock is up 155.6% year-to-date.
Over the past three months, Cidara Therapeutics' consensus EPS estimate for the current year has increased 9.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Black Diamond belongs to the Medical - Biomedical and Genetics industry, a group that includes 483 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have gained 4.4% this year, meaning that BDTX is performing better in terms of year-to-date returns. Cidara Therapeutics is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Black Diamond and Cidara Therapeutics. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Black Diamond (BDTX - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Black Diamond is a member of the Medical sector. This group includes 972 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Black Diamond is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for BDTX's full-year earnings has moved 37.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BDTX has gained about 53.3% so far this year. Meanwhile, stocks in the Medical group have lost about 1.9% on average. This means that Black Diamond is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Cidara Therapeutics (CDTX - Free Report) . The stock is up 155.6% year-to-date.
Over the past three months, Cidara Therapeutics' consensus EPS estimate for the current year has increased 9.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Black Diamond belongs to the Medical - Biomedical and Genetics industry, a group that includes 483 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have gained 4.4% this year, meaning that BDTX is performing better in terms of year-to-date returns. Cidara Therapeutics is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Black Diamond and Cidara Therapeutics. These stocks will be looking to continue their solid performance.